Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Gilteritinib→

Gilteritinib Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1254053-43-4
Molecular formula
C29H44N8O3
Molecular weight
552.7 g/mol
Drug class
FMS-like tyrosine kinase 3 (FLT3) inhibitortargeted antineoplastic kinase inhibitor
Mechanism of action
Inhibits FLT3 receptor tyrosine kinase signalling, including FLT3-ITD and FLT3-TKD mutations, reducing downstream proliferative signalling in FLT3-mutated leukaemic cells. It also inhibits additional kinases at clinically relevant concentrations.
Indications / reported uses
  • Treatment of adults with relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation detected by an FDA-approved test; specialist haematology use

Sources: US DailyMed — XOSPATA (gilteritinib) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Gilteritinib Environmental Risk Assessment (ERA) (the Gilteritinib ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.